Financials Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
29.77 ^CNY	-0.33%		-0.77%	+9.29%

Apr. 26	Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4%	MT

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	8,804	18,713	20,540	16,669	19,957	21,756	-
Enterprise Value (EV) ¹	8,804	18,713	20,540	16,669	19,957	21,756	21,756
P/E ratio	54.9 x	100 x	50.7 x	28.3 x	32.5 x	30.3 x	26.2 x
Yield	0.37%	-	0.2%	-	0.73%	0.34%	0.37%
Capitalization / Revenue	9.62 x	17.8 x	10.4 x	6.93 x	8.57 x	7.37 x	6.51 x
EV / Revenue	9.62 x	17.8 x	10.4 x	6.93 x	8.57 x	7.37 x	6.51 x
EV / EBITDA	-	-	-	21.2 x	24 x	24.5 x	21.6 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	11 x	19.4 x	3.25 x	2.43 x	2.69 x	2.71 x	2.47 x
Nbr of stocks (in thousands)	489,218	492,435	732,783	732,360	732,646	730,818	-
Reference price ²	18.00	38.00	28.03	22.76	27.24	29.77	29.77
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	915.7	1,050	1,972	2,405	2,329	2,952	3,340
EBITDA ¹	-	-	-	785.5	832.8	886.5	1,009
EBIT ¹	180	220.3	460.4	663.4	695.2	812	938.3
Operating Margin	19.66%	20.98%	23.35%	27.58%	29.85%	27.51%	28.1%
Earnings before Tax (EBT) ¹	189	217.2	458	660.4	688.1	809.7	936.3
Net income ¹	160.4	186	391.1	587.1	612.1	720	832.7
Net margin	17.52%	17.71%	19.83%	24.41%	26.29%	24.39%	24.93%
EPS ²	0.3280	0.3793	0.5530	0.8032	0.8384	0.9833	1.137
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	0.0674	-	0.0560	-	0.2000	0.1000	0.1100
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2024 Q1
Net sales ¹	435.6
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	121.9
Net margin	27.99%
EPS	-
Dividend per Share	-
Announcement Date	4/26/24

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	22.3%	21.2%	7.04%	8.9%	8.58%	8.97%	9.43%
ROA (Net income/ Total Assets)	-	-	-	7.36%	-	7.9%	8.35%
Assets ¹	-	-	-	7,982	-	9,114	9,972
Book Value Per Share ²	1.640	1.960	8.630	9.380	10.10	11.00	12.10
Cash Flow per Share ²	0.3900	0.4000	0.5600	-	0.9300	0.8900	1.730
Capex ¹	41.1	40.1	325	378	376	179	123
Capex / Sales	4.49%	3.82%	16.47%	15.72%	16.13%	6.06%	3.67%
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pacific Shuanglin Bio-pharmacy Co., LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.77 CNY

Average target price

30 CNY

Spread / Average Target

+0.77%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD	+9.29%	3.01B
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.97%	39.82B
UCB	+56.59%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-13.53%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.82%	11.95B
INCYTE CORPORATION	-15.35%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.58%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.71B
INNOVENT BIOLOGICS, INC.	-7.02%	8.12B

Biopharmaceuticals